Semax is a synthetic heptapeptide drug developed in Russia from the adrenocorticotropic hormone (ACTH) fragment 4-10 with an added C-terminal tripeptide Pro-Gly-Pro. Originally developed for stroke and traumatic brain injury treatment, Semax has demonstrated significant nootropic properties including enhanced memory, improved attention, and neuroprotection. The peptide works through multiple mechanisms including increased BDNF expression, modulation of the dopaminergic and serotonergic systems, and effects on neuronal gene expression. Unlike ACTH, Semax does not affect adrenal function, eliminating corticosteroid-related side effects while maintaining neurotropic activity.
| Research Status | Approved in Russia |
|---|---|
| Half-Life | Minutes (rapid absorption) |
| Administration | Intranasal |
| Typical Dosage | 200-600 mcg |
| Molecular Weight | 813.9 Da |
| Molecular Formula | C37H51N9O10S |
Increases BDNF expression, modulates dopamine and serotonin systems, enhances neuroplasticity.
All information is presented for Research Use Only (RUO). Not medical advice.